XBiotech Inc. (XBIT) - Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. XBiotech Inc. is a pre-market biopharmaceutical company developing True Human™ monoclonal antibodies. The company focuses on anti-infective and anti-inflammatory candidates, specifically targeting interleukin-1 alpha (IL-1a). As of June 30, 2026, the company had 30,487,731 shares of common stock outstanding and 87 employees, though a workforce reduction was implemented subsequent to the period end.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(6.7) million | $(12.2) million |
| Net Loss Per Share (Basic/Diluted) | $(0.22) | $(0.40) |
| Operating Expenses | $6.1 million | $12.4 million |
| Cash and Cash Equivalents (End of Period) | $109.5 million | |
| Net Cash Used in Operating Activities | $(13.5) million (Six Months) | |
| Total Liabilities | $5.2 million | |
| Shareholders' Equity | $128.5 million |
Material Changes vs. Prior Period
- Net Loss: The net loss for the three months ended June 30, 2026, increased to $6.7 million from $1.8 million in the same period in 2025. This increase was primarily driven by a foreign exchange loss of $1.4 million in Q2 2026, compared to a gain of $3.1 million in Q2 2025.
- Operating Expenses: Total operating expenses decreased slightly to $6.1 million in Q2 2026 from $6.3 million in Q2 2025. For the six-month period, expenses dropped significantly to $12.4 million from $19.9 million in 2025. This reduction is largely attributable to the absence of a $4.0 million bonus and $3.0 million in stock-based compensation awarded to the former CEO in March 2025.
- Foreign Exchange: The company recorded a foreign exchange loss of $2.5 million for the six months ended June 30, 2026, reversing a gain of $3.4 million in the prior year period due to fluctuations between the U.S. and Canadian dollars.
- Other Income: Other income for the six months ended June 30, 2026, included $1.0 million primarily from an Employee Retention Credit received from the IRS.
Outlook, Risks, and Management Commentary
- Revenue Outlook: Management does not expect to generate any revenue in 2026. The company anticipates incurring significant and increasing operating losses as it advances drug candidates through clinical testing.
- Liquidity: With $109.5 million in cash and cash equivalents, management expects sufficient liquidity to fund operations for at least 12 months from the date of the report.
- Clinical Progress: The company has successfully completed a Phase II clinical study in oncology and is engaging with the FDA regarding the regulatory path. A new Phase II trial for active axial spondyloarthritis was launched in the past quarter.
- Risks: Key risks include the uncertainty of regulatory approval, the success of clinical trials, the ability to recruit patients, and the need for additional financing to achieve profitability. The company also faces risks related to foreign currency fluctuations and intellectual property protection.
- Workforce Reduction: A workforce reduction was implemented subsequent to June 30, 2026. Management does not expect the related costs to be material.
Investor Verification Checklist
- Verify the timeline and regulatory feedback regarding the completed Phase II oncology study and the new Phase II axial spondyloarthritis trial.
- Monitor cash burn rate relative to the $109.5 million cash balance to assess the runway for future financing needs.
- Review the impact of the recent workforce reduction on operational capacity and future expense guidance.
- Assess the volatility of foreign exchange impacts on the bottom line given the company's Canadian incorporation and U.S. operations.
- Confirm the status of the Janssen Transaction milestone payments, noting that none have been earned as of June 30, 2026.